Bridges Investment Counsel Inc. cut its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 23.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,760 shares of the biopharmaceutical company’s stock after selling 4,600 shares during the period. Bridges Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of BMY. Connecticut Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the first quarter valued at approximately $224,000. Birmingham Capital Management Co. Inc. AL raised its position in Bristol-Myers Squibb by 4.4% during the first quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after purchasing an additional 3,000 shares during the period. HGK Asset Management Inc. grew its stake in shares of Bristol-Myers Squibb by 20.8% during the first quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after buying an additional 53,221 shares during the last quarter. Investment Partners Ltd. OH ADV grew its stake in shares of Bristol-Myers Squibb by 1.4% during the first quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 274 shares during the last quarter. Finally, Goelzer Investment Management Inc. grew its stake in shares of Bristol-Myers Squibb by 85.4% during the first quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after buying an additional 34,735 shares during the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Friday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The stock has a market capitalization of $102,154.63, a P/E ratio of 21.09, a P/E/G ratio of 2.37 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the company earned $0.77 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.56%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

A number of research analysts have recently commented on BMY shares. UBS reaffirmed a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a research note on Monday, October 9th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets reaffirmed a “sell” rating and set a $49.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Finally, Citigroup upped their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $64.93.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Sold by Bridges Investment Counsel Inc.” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/17/bristol-myers-squibb-company-bmy-shares-sold-by-bridges-investment-counsel-inc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.